Table 4.

Bivariate and multivariate analysis of the impact of acquisition type in mortality among patients with bacteremia due to carbapenemase-producing K. pneumoniae or E. coli

Characteristic		Dead/exposed (%)	OR (95% CI)	P value	Adjusted OR (95% CI)	P value
OXA-48 carbapenemase	Yes	21/47 (44.7)	0.72 (0.45–1.14)	0.18	–	–
	No	13/21 (61.9)	Ref
KPC carbapenemase	Yes	9/16 (56.3)	1.17 (0.69–1.96)	0.56	–	–
	No	25/52 (40.0)	Ref
MBL carbapenemase	Yes	5/6 (83.3)	1.78 (1.14–2.85)	0.08	–	–
	No	29/62 (46.8)	Ref
High-risk clone	Yes	26/51 (51.0)	1.01 (0.61–1.92)	0.77	–	–
	No	8/17 (47.1)	Ref
Age in years	< 65	14/24 (58.3)	0.78 (0.49–1.25)	0.31	–	–
	≥ 65	20/44 (45.5)	Ref
Sex	Female	17/38 (44.7)	0.78 (0.49–1.26)	0.32	–	–
	Male	17/30 (56.7)	Ref
Fatal underlying disease	Yes	25/69 (64.1)	2.08 (1.14–3.84)	0.007	6.20 (1.85–20.70)	0.003
	No	9/29 (31.0)	Ref
Mechanical ventilation	Yes	12/15 (80.9)	1.96 (1.28–2.94)	0.008	–	–
	No	22/53 (41.5)	Ref
High-risk source	Yes	22/35 (62.9)	1.57 (1.03–4.16)	0.02	3.81 (1.20–12.10)	0.023
	No	12/33 (36.4)	Ref
Active empirical therapy	Yes	8/19 (42.1)	0.79 (0.44–1.44)	0.41	–	-
	No	26/49 (53.1)	Ref
Nosocomial acquisition	Yes	26/43 (60.5)	1.92 (1.02–3.57)	0.02	4.00 (1.21–13.19)	0.022
	No	8/25 (32.0)	Ref